Skip to content
2000
Volume 24, Issue 2
  • ISSN: 1871-5273
  • E-ISSN: 1996-3181

Abstract

Background

Parkinson's Disease (PD) is frequently associated with a spectrum of sleep-related disorders, including insomnia, Excessive Daytime Sleepiness (EDS), REM sleep Behaviour Disorder (RBD), Restless Legs Syndrome (RLS), and Sleep-related Breathing Disorders (SBDs). These disorders significantly impact PD patients' Quality of Life (QoL) and present unique diagnostic and therapeutic challenges.

Methods

This review has explored the intricate relationship between PD and sleep-related disorders, emphasizing their distinctive features and underlying neurobiological mechanisms. It aimed to consolidate current knowledge to optimize clinical management and improve patient care. The profound impact of these disorders on QoL has been evaluated, along with precise diagnostic methodologies. Additionally, various therapeutic strategies, including pharmacological treatments, nonpharmacological interventions, and device-aided therapies, have been examined.

Results

Sleep-related disorders are prevalent among PD patients. Specifically, RBD exhibits a prevalence of 40-50%, often preceding the onset of motor symptoms, indicating its potential as an early marker of PD. Despite their significant impact on QoL, these non-motor symptoms are frequently under-recognized and inadequately managed in clinical practice. Pharmacological treatments, along with nonpharmacological interventions, like cognitive-behavioral therapy for insomnia and lifestyle modifications, have shown varied efficacy. Device-aided therapies have also demonstrated the potential to improve sleep-related disorders and overall non-motor symptom burden.

Conclusion

Effective management of sleep-related disorders in PD calls for personalized, comprehensive, and multimodal therapeutic approaches. This requires the collaborative efforts of neurologists, sleep specialists, psychiatrists, and other healthcare professionals. Future research should focus on the intricate relationship between PD and sleep disorders, aiming to develop innovative treatments and significantly improve patient outcomes.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/cnsnddt/10.2174/0118715273314675240820191447
2024-09-05
2025-09-08

  • From This Site

    /content/journals/cnsnddt/10.2174/0118715273314675240820191447
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. MoustafaA.A. ChakravarthyS. PhillipsJ.R. Motor symptoms in Parkinson’s disease: A unified framework.Neurosci. Biobehav. Rev.20166872774010.1016/j.neubiorev.2016.07.010 27422450
     [Google Scholar]
  2. MaggiG. VitaleC. CercielloF. SantangeloG. Sleep and wakefulness disturbances in Parkinson’s disease: A meta-analysis on prevalence and clinical aspects of REM sleep behavior disorder, excessive daytime sleepiness and insomnia.Sleep Med. Rev.20236810175910.1016/j.smrv.2023.101759 36708642
     [Google Scholar]
  3. SuzukiK. OkumaY. UchiyamaT. Impact of sleep-related symptoms on clinical motor subtypes and disability in Parkinson’s disease: A multicentre cross-sectional study.J. Neurol. Neurosurg. Psychiatry2017881195395910.1136/jnnp‑2017‑316136 28847794
     [Google Scholar]
  4. TallP. QamarM.A. RosenzweigI. The Park Sleep subtype in Parkinson’s disease: From concept to clinic.Expert Opin. Pharmacother.202324151725173610.1080/14656566.2023.2242786 37561080
     [Google Scholar]
  5. SchenckC.H. Cochen de CockV. LewisS.J.G. TachibanaN. KushidaC. FerriR. Partial endorsement of: “Video-polysomnography procedures for diagnosis of rapid eye movement sleep behavior disorder (RBD) and the identification of its prodromal stages: Guidelines from the International RBD Study Group” by the World Sleep Society.Sleep Med.202311013714510.1016/j.sleep.2023.07.012 37579534
     [Google Scholar]
  6. de BergeyckR. GeoffroyP.A. Insomnia in neurological disorders: Prevalence, mechanisms, impact and treatment approaches.Rev. Neurol. (Paris)2023179776778110.1016/j.neurol.2023.08.008 37620177
     [Google Scholar]
  7. LoddoG. Calandra-BuonauraG. SambatiL. The treatment of sleep disorders in Parkinson’s disease: From research to clinical practice.Front. Neurol.201784210.3389/fneur.2017.00042 28261151
     [Google Scholar]
  8. ZhuK. van HiltenJ.J. MarinusJ. The course of insomnia in Parkinson’s disease.Parkinsonism Relat. Disord.201633515710.1016/j.parkreldis.2016.09.010 27639814
     [Google Scholar]
  9. SchützL Sixel-DöringF HermannW Management of sleep disturbances in parkinson's disease.J Parkinsons Dis20221272029205810.3233/JPD‑212749 35938257
     [Google Scholar]
  10. FengF. CaiY. HouY. OuR. JiangZ. ShangH. Excessive daytime sleepiness in Parkinson’s disease: A systematic review and meta-analysis.Parkinsonism Relat. Disord.20218513314010.1016/j.parkreldis.2021.02.016 33637423
     [Google Scholar]
  11. St LouisE.K. BoeveA.R. BoeveB.F. REM sleep behavior disorder in Parkinson’s Disease and other synucleinopathies.Mov. Disord.201732564565810.1002/mds.27018 28513079
     [Google Scholar]
  12. IranzoA. The REM sleep circuit and how its impairment leads to REM sleep behavior disorder.Cell Tissue Res.2018373124526610.1007/s00441‑018‑2852‑8 29846796
     [Google Scholar]
  13. DiaconuȘ. Falup-pecurariuO. ȚînțD. Falup-PecurariuC. REM sleep behaviour disorder in Parkinson’s disease (Review).Exp. Ther. Med.202122281210.3892/etm.2021.10244 34131435
     [Google Scholar]
  14. Alonso-NavarroH. García-MartínE. AgúndezJ.A.G. Jiménez-JiménezF.J. Association between restless legs syndrome and other movement disorders.Neurology2019922094896410.1212/WNL.0000000000007500 31004074
     [Google Scholar]
  15. TrenkwalderC. WinkelmannJ. InoueY. PaulusW. Restless legs syndrome—current therapies and management of augmentation.Nat. Rev. Neurol.201511843444510.1038/nrneurol.2015.122 26215616
     [Google Scholar]
  16. YuQ. HuX. ZhengT. Obstructive sleep apnea in Parkinson’s disease: A prevalent, clinically relevant and treatable feature.Parkinsonism Relat. Disord.202311510579010.1016/j.parkreldis.2023.105790 37541789
     [Google Scholar]
  17. HuntJ. CoulsonE.J. RajnarayananR. OsterH. VidenovicA. RawashdehO. Sleep and circadian rhythms in Parkinson’s disease and preclinical models.Mol. Neurodegener.2022171210.1186/s13024‑021‑00504‑w 35000606
     [Google Scholar]
  18. GrosP. VidenovicA. Overview of sleep and circadian rhythm disorders in parkinson disease.Clin. Geriatr. Med.202036111913010.1016/j.cger.2019.09.005 31733692
     [Google Scholar]
  19. AmaraA.W. ChahineL.M. VidenovicA. Treatment of sleep dysfunction in parkinson’s disease.Curr. Treat. Options Neurol.20171972610.1007/s11940‑017‑0461‑6 28567500
     [Google Scholar]
  20. ZuzuárreguiJ.R.P. DuringE.H. Sleep issues in parkinson’s disease and their management.Neurotherapeutics20201741480149410.1007/s13311‑020‑00938‑y 33029723
     [Google Scholar]
  21. SchenckC.H. REM sleep behavior disorder as a complex condition with heterogeneous underlying disorders: Clinical management and prognostic implications (Commentary).Sleep Breath.20222631289129810.1007/s11325‑022‑02574‑6 35239134
     [Google Scholar]
  22. ZahedH. ZuzuarreguiJ.R.P. GilronR. DenisonT. StarrP.A. LittleS. The neurophysiology of sleep in parkinson’s disease.Mov. Disord.20213671526154210.1002/mds.28562 33826171
     [Google Scholar]
  23. ZhaiS. CuiQ. SimmonsD.V. SurmeierD.J. Distributed dopaminergic signaling in the basal ganglia and its relationship to motor disability in Parkinson’s disease.Curr. Opin. Neurobiol.20238310279810.1016/j.conb.2023.102798 37866012
     [Google Scholar]
  24. SurmeierD.J. ObesoJ.A. HallidayG.M. Selective neuronal vulnerability in Parkinson disease.Nat. Rev. Neurosci.201718210111310.1038/nrn.2016.178 28104909
     [Google Scholar]
  25. SiegelJ.M. The neurotransmitters of sleep.J. Clin. Psychiatry200465Suppl. 1647 15575797
     [Google Scholar]
  26. XieL. KangH. XuQ. Sleep drives metabolite clearance from the adult brain.Science2013342615637337710.1126/science.1241224 24136970
     [Google Scholar]
  27. EideP.K. VinjeV. PrippA.H. MardalK.A. RingstadG. Sleep deprivation impairs molecular clearance from the human brain.Brain2021144386387410.1093/brain/awaa443 33829232
     [Google Scholar]
  28. JankovicJ. TanE.K. Parkinson’s disease: Etiopathogenesis and treatment.J. Neurol. Neurosurg. Psychiatry202091879580810.1136/jnnp‑2019‑322338 32576618
     [Google Scholar]
  29. AtaideM. FrancoC.M.R. LinsO.G. Daytime sleepiness and Parkinson’s disease: The contribution of the multiple sleep latency test.Sleep Disord.201420141910.1155/2014/767181 25126427
     [Google Scholar]
  30. MarinusJ. VisserM. van HiltenJ.J. LammersG.J. StiggelboutA.M. Assessment of sleep and sleepiness in Parkinson disease.Sleep20032681049105410.1093/sleep/26.8.1049 14746389
     [Google Scholar]
  31. StefaniA. HöglB. Sleep in Parkinson’s disease.Neuropsychopharmacology202045112112810.1038/s41386‑019‑0448‑y 31234200
     [Google Scholar]
  32. ChungS. BohnenN.I. AlbinR.L. FreyK.A. MüllerM.L.T.M. ChervinR.D. Insomnia and sleepiness in Parkinson disease: Associations with symptoms and comorbidities.J. Clin. Sleep Med.20139111131113710.5664/jcsm.3150 24235893
     [Google Scholar]
  33. TaximaimaitiR. LuoX. WangX.P. Pharmacological and non-pharmacological treatments of sleep disorders in Parkinson’s disease.Curr. Neuropharmacol.202119122233224910.2174/1570159X19666210517115706 33998990
     [Google Scholar]
  34. TaguchiS. KoideH. OiwaH. Antiparkinsonian drugs as potent contributors to nocturnal sleep in patients with Parkinson’s disease.PLoS One2021167e025527410.1371/journal.pone.0255274 34320022
     [Google Scholar]
  35. ScangaA. LafontaineA.L. KaminskaM. An overview of the effects of levodopa and dopaminergic agonists on sleep disorders in Parkinson’s disease.J. Clin. Sleep Med.20231961133114410.5664/jcsm.10450 36716191
     [Google Scholar]
  36. HöglundA. HagellP. BromanJ.E. PålhagenS. SorjonenK. FredriksonS. A 10-year follow-up of excessive daytime sleepiness in Parkinson’s Disease.Parkinsons Dis.201920191710.1155/2019/5708515 31583073
     [Google Scholar]
  37. AbbottR.D. RossG.W. WhiteL.R. Excessive daytime sleepiness and subsequent development of Parkinson disease.Neurology20056591442144610.1212/01.wnl.0000183056.89590.0d 16275833
     [Google Scholar]
  38. JinH. ZhangJ.R. ShenY. LiuC.F. Clinical significance of rem sleep behavior disorders and other non-motor symptoms of parkinsonism.Neurosci. Bull.201733557658410.1007/s12264‑017‑0164‑8 28770440
     [Google Scholar]
  39. BoucettaS. SalimiA. DadarM. JonesB.E. CollinsD.L. Dang-VuT.T. Structural brain alterations associated with rapid eye movement sleep behavior disorder in parkinson’s disease.Sci. Rep.2016612678210.1038/srep26782 27245317
     [Google Scholar]
  40. ZimanskyL. MunteanM.L. LehaA. MollenhauerB. TrenkwalderC. Sixel-DöringF. Incidence and progression of rapid eye movement behavior disorder in early parkinson’s disease.Mov. Disord. Clin. Pract. (Hoboken)20218453454010.1002/mdc3.13168 33977115
     [Google Scholar]
  41. KroegerD. FerrariL.L. PetitG. Cholinergic, Glutamatergic, and GABAergic Neurons of the pedunculopontine tegmental nucleus have distinct effects on sleep/wake behavior in mice.J. Neurosci.20173751352136610.1523/JNEUROSCI.1405‑16.2016 28039375
     [Google Scholar]
  42. ChanP.C. LeeH.H. HongC.T. HuC.J. WuD. REM sleep behavior disorder (RBD) in dementia with lewy bodies (DLB).Behav. Neurol.2018201811010.1155/2018/9421098 30018672
     [Google Scholar]
  43. BoeveB.F. SilberM.H. FermanT.J. LucasJ.A. ParisiJ.E. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy.Mov. Disord.200116462263010.1002/mds.1120 11481685
     [Google Scholar]
  44. Mateo-MonteroR.C. Pedrera-MazarroA. Martín-PalomequeG. Clinical and genetical study of a familial form of REM sleep behavior disorder.Clin. Neurol. Neurosurg.201817513013310.1016/j.clineuro.2018.09.035 30419424
     [Google Scholar]
  45. FermanT.J. BoeveB.F. SmithG.E. REM sleep behavior disorder and dementia.Neurology199952595195710.1212/WNL.52.5.951 10102411
     [Google Scholar]
  46. MaoJ. HuangX. YuJ. Association between REM sleep behavior disorder and cognitive dysfunctions in parkinson’s disease: A systematic review and meta-analysis of observational studies.Front. Neurol.20201157787410.3389/fneur.2020.577874 33240202
     [Google Scholar]
  47. WallaceD.M. WohlgemuthW.K. TrottiL.M. Practical evaluation and management of insomnia in parkinson’s disease: A review.Mov. Disord. Clin. Pract. (Hoboken)20207325026610.1002/mdc3.12899 32258222
     [Google Scholar]
  48. XuZ. AndersonK.N. PaveseN. Longitudinal studies of sleep disturbances in parkinson’s disease.Curr. Neurol. Neurosci. Rep.2022221063565510.1007/s11910‑022‑01223‑5 36018498
     [Google Scholar]
  49. XiangY. XuQ. SunQ. Clinical features and correlates of excessive daytime sleepiness in parkinson’s disease.Front. Neurol.20191012110.3389/fneur.2019.00121 30837940
     [Google Scholar]
  50. YeG. XuX. ZhouL. ZhaoA. ZhuL. LiuJ. Evolution patterns of probable REM sleep behavior disorder predicts Parkinson’s disease progression.NPJ Parkinsons Dis.2022813610.1038/s41531‑022‑00303‑0 35383198
     [Google Scholar]
  51. SuzukiK. MiyamotoM. MiyamotoT. HirataK. Restless legs syndrome and leg motor restlessness in parkinson’s disease.Parkinsons Dis.201520151910.1155/2015/490938 26504610
     [Google Scholar]
  52. MinibajevaO. ZeltiņaE. KarelisG. KurjāneN. ĶēniņaV. Clinical symptoms influencing parkinson’s patients’ quality of life in Latvia: A Single-center cohort study.Medicina (Kaunas)202359593510.3390/medicina59050935 37241166
     [Google Scholar]
  53. MonaghanA.S. HooymanA. DibbleL.E. MehtaS.H. PetersonD.S. Cognitive predictors of responsiveness to reactive step training in people with parkinson’s disease at fall-risk.Neurosci. Lett.202381713751710.1016/j.neulet.2023.137517 37832815
     [Google Scholar]
  54. ColauttiL. IannelloP. SilveriM.C. AntoniettiA. Decision making in Parkinson’s disease: An analysis of the studies using the Iowa Gambling Task.Eur. J. Neurosci.202154107513754910.1111/ejn.15497 34655122
     [Google Scholar]
  55. ChenJ. TuersunY. YangJ. Association of depression symptoms and sleep quality with state-trait anxiety in medical university students in Anhui Province, China: A mediation analysis.BMC Med. Educ.202222162710.1186/s12909‑022‑03683‑2 35982434
     [Google Scholar]
  56. de FigueiredoJ.M. ZhuB. PatelA.S. KohnR. KooB.B. LouisE.D. Differential impact of resilience on demoralization and depression in Parkinson disease.Front. Psychiatry202314120701910.3389/fpsyt.2023.1207019 37559912
     [Google Scholar]
  57. DiaconuŞ. Falup-PecurariuC. Personalized assessment of insomnia and sleep quality in patients with parkinson’s disease.J. Pers. Med.202212232210.3390/jpm12020322 35207811
     [Google Scholar]
  58. Ben SimonE. WalkerM.P. Sleep loss causes social withdrawal and loneliness.Nat. Commun.201891314610.1038/s41467‑018‑05377‑0 30108218
     [Google Scholar]
  59. HavlikovaE. van DijkJ.P. NagyovaI. The impact of sleep and mood disorders on quality of life in Parkinson’s disease patients.J. Neurol.2011258122222222910.1007/s00415‑011‑6098‑6 21614432
     [Google Scholar]
  60. ChaudhuriK.R. PalS. DiMarcoA. The Parkinson’s disease sleep scale: A new instrument for assessing sleep and nocturnal disability in Parkinson’s disease.J. Neurol. Neurosurg. Psychiatry200273662963510.1136/jnnp.73.6.629 12438461
     [Google Scholar]
  61. StavitskyK. Cronin-GolombA. Sleep quality in Parkinson disease: An examination of clinical variables.Cogn. Behav. Neurol.2011242434910.1097/WNN.0b013e31821a4a95 21537164
     [Google Scholar]
  62. TangX. YangJ. ZhuY. High PSQI score is associated with the development of dyskinesia in Parkinson’s disease.NPJ Parkinsons Dis.20228112410.1038/s41531‑022‑00391‑y 36175559
     [Google Scholar]
  63. KumarS. BhatiaM. BehariM. Excessive daytime sleepiness in Parkinson’s disease as assessed by epworth sleepiness scale (ESS).Sleep Med.20034433934210.1016/S1389‑9457(03)00105‑9 14592307
     [Google Scholar]
  64. FrazzittaG. MaestriR. FerrazzoliD. Multidisciplinary intensive rehabilitation treatment improves sleep quality in Parkinson’s disease.J. Clin. Mov. Disord.2015211110.1186/s40734‑015‑0020‑9 26788347
     [Google Scholar]
  65. MischleyL.K. LauR.C. BennettR.D. Role of diet and nutritional supplements in Parkinson’s disease progression.Oxid. Med. Cell. Longev.2017201711910.1155/2017/6405278 29081890
     [Google Scholar]
  66. KutscherS.J. FarshidpanahS. ClaassenD.O. Sleep dysfunction and its management in Parkinson’s disease.Curr. Treat. Options Neurol.201416830410.1007/s11940‑014‑0304‑7 24930678
     [Google Scholar]
  67. VoyseyZ.J. BarkerR.A. LazarA.S. The Treatment of Sleep Dysfunction in Neurodegenerative Disorders.Neurotherapeutics202118120221610.1007/s13311‑020‑00959‑7 33179197
     [Google Scholar]
  68. HumbertM. FindleyJ. Hernandez-ConM. ChahineL.M. Cognitive behavioral therapy for insomnia in Parkinson’s disease: A case series.NPJ Parkinsons Dis.2017312510.1038/s41531‑017‑0027‑z 28765835
     [Google Scholar]
  69. CoeS. FranssenM. CollettJ. Physical activity, fatigue, and sleep in people with parkinson’s disease: A secondary per protocol analysis from an intervention trial.Parkinsons Dis.201820181610.1155/2018/1517807 30258564
     [Google Scholar]
  70. HuangH.T. HuangT.W. HongC.T. Bright light therapy for parkinson disease: A literature review and meta-analysis of randomized controlled trials.Biology (Basel)20211011120510.3390/biology10111205 34827198
     [Google Scholar]
  71. PrengerM.T.M. MadrayR. Van HedgerK. AnelloM. MacDonaldP.A. Social symptoms of Parkinson’s disease.Parkinsons Dis.2020202018846544 33489081
     [Google Scholar]
  72. MenzaM. DobkinR.D. MarinH. Treatment of insomnia in Parkinson’s disease: A controlled trial of eszopiclone and placebo.Mov. Disord.201025111708171410.1002/mds.23168 20589875
     [Google Scholar]
  73. Rios RomenetsS. CretiL. FichtenC. Doxepin and cognitive behavioural therapy for insomnia in patients with Parkinson’s disease – A randomized study.Parkinsonism Relat. Disord.201319767067510.1016/j.parkreldis.2013.03.003 23561946
     [Google Scholar]
  74. DowlingG.A. MastickJ. CollingE. CarterJ.H. SingerC.M. AminoffM.J. Melatonin for sleep disturbances in Parkinson’s disease.Sleep Med.20056545946610.1016/j.sleep.2005.04.004 16084125
     [Google Scholar]
  75. MedeirosC.A.M. Carvalhedo de BruinP.F. LopesL.A. MagalhãesM.C. de Lourdes SeabraM. Sales de BruinV.M. Effect of exogenous melatonin on sleep and motor dysfunction in Parkinson’s disease.J. Neurol.2007254445946410.1007/s00415‑006‑0390‑x 17404779
     [Google Scholar]
  76. ShenY. HuangJ.Y. LiJ. LiuC.F. Excessive daytime sleepiness in Parkinson’s Disease.Chin. Med. J.2018131897498110.4103/0366‑6999.229889 29664059
     [Google Scholar]
  77. AdlerC.H. CavinessJ.N. HentzJ.G. LindM. TiedeJ. Randomized trial of modafinil for treating subjective daytime sleepiness in patients with Parkinson’s disease.Mov. Disord.200318328729310.1002/mds.10390 12621632
     [Google Scholar]
  78. HöglB. SaletuM. BrandauerE. Modafinil for the treatment of daytime sleepiness in Parkinson’s disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial.Sleep2002258626610.1093/sleep/25.8.62 12489899
     [Google Scholar]
  79. LouJ.S. DimitrovaD.M. ParkB.S. Using modafinil to treat fatigue in Parkinson disease: A double-blind, placebo-controlled pilot study.Clin. Neuropharmacol.200932630531010.1097/WNF.0b013e3181aa916a 19620846
     [Google Scholar]
  80. OndoW.G. FayleR. AtassiF. JankovicJ. Modafinil for daytime somnolence in Parkinson’s disease: Double blind, placebo controlled parallel trial.J. Neurol. Neurosurg. Psychiatry200576121636163910.1136/jnnp.2005.065870 16291885
     [Google Scholar]
  81. PostumaR.B. LangA.E. MunhozR.P. Caffeine for treatment of Parkinson disease.Neurology201279765165810.1212/WNL.0b013e318263570d 22855866
     [Google Scholar]
  82. PostumaR.B. AnangJ. PelletierA. Caffeine as symptomatic treatment for Parkinson disease (Café-PD).Neurology201789171795180310.1212/WNL.0000000000004568 28954882
     [Google Scholar]
  83. BücheleF. HackiusM. SchreglmannS.R. Sodium oxybate for excessive daytime sleepiness and sleep disturbance in parkinson disease.JAMA Neurol.201875111411810.1001/jamaneurol.2017.3171 29114733
     [Google Scholar]
  84. SuzukiK. MiyamotoM. MiyamotoT. Istradefylline improves daytime sleepiness in patients with Parkinson’s disease: An open-label, 3-month study.J. Neurol. Sci.201738023023310.1016/j.jns.2017.07.045 28870576
     [Google Scholar]
  85. MatsuuraK. KajikawaH. TabeiK. The effectiveness of istradefylline for the treatment of gait deficits and sleepiness in patients with Parkinson’s disease.Neurosci. Lett.201866215816110.1016/j.neulet.2017.10.018 29031781
     [Google Scholar]
  86. LajoieA.C. GuY. LimA. BenedettiA. KaminskaM. Adherence to continuous positive airway pressure for the treatment of obstructive sleep apnea in neurodegenerative diseases: A systematic review.Sleep Med. Rev.20237110183610.1016/j.smrv.2023.101836 37586145
     [Google Scholar]
  87. WinkelmannJ. AllenR.P. HöglB. Treatment of restless legs syndrome: Evidence‐based review and implications for clinical practice (Revised 2017) §.Mov. Disord.20183371077109110.1002/mds.27260 29756335
     [Google Scholar]
  88. Cochen De CockV. Therapies for restless legs in parkinson’s disease.Curr. Treat. Options Neurol.201921115610.1007/s11940‑019‑0596‑8 31707535
     [Google Scholar]
  89. IftikharI.H. AlghothaniL. TrottiL.M. Gabapentin enacarbil, pregabalin and rotigotine are equally effective in restless legs syndrome: A comparative meta‐analysis.Eur. J. Neurol.201724121446145610.1111/ene.13449 28888061
     [Google Scholar]
  90. GilatM. MarshallN.S. TestelmansD. BuyseB. LewisS.J.G. A critical review of the pharmacological treatment of REM sleep behavior disorder in adults: Time for more and larger randomized placebo-controlled trials.J. Neurol.2022269112514810.1007/s00415‑020‑10353‑0 33410930
     [Google Scholar]
  91. HowellM. AvidanA.Y. Foldvary-SchaeferN. Management of REM sleep behavior disorder: An american academy of sleep medicine systematic review, meta-analysis, and GRADE assessment.J. Clin. Sleep Med.202319476981010.5664/jcsm.10426 36515150
     [Google Scholar]
  92. MadridJ. BenningerD.H. Non-invasive brain stimulation for Parkinson’s disease: Clinical evidence, latest concepts and future goals: A systematic review.J. Neurosci. Methods202134710895710.1016/j.jneumeth.2020.108957 33017643
     [Google Scholar]
  93. JennerP. MoriA. KandaT. Can adenosine A2A receptor antagonists be used to treat cognitive impairment, depression or excessive sleepiness in Parkinson’s disease?Parkinsonism Relat. Disord.202080S28S3610.1016/j.parkreldis.2020.09.022 33349577
     [Google Scholar]
  94. LetaV. DafsariH.S. SauerbierA. Personalised advanced therapies in parkinson’s disease: The role of non-motor symptoms profile.J. Pers. Med.202111877310.3390/jpm11080773 34442417
     [Google Scholar]
  95. ZhangX. XieA. Improvement of subthalamic nucleus deep brain stimulation in sleeping symptoms in parkinson’s disease: A meta-analysis.Parkinsons Dis.201920191910.1155/2019/6280896 31687125
     [Google Scholar]
  96. StefaniA. CerroniR. PierantozziM. Deep brain stimulation in Parkinson’s disease patients and routine 6‐OHDA rodent models: Synergies and pitfalls.Eur. J. Neurosci.20215372322234310.1111/ejn.14950 32853415
     [Google Scholar]
  97. Baumann-VogelH. ImbachL.L. SürücüO. The impact of subthalamic deep brain stimulation on sleep–wake behavior: A prospective electrophysiological study in 50 parkinson patients.Sleep2017405zsx03310.1093/sleep/zsx033 28369624
     [Google Scholar]
  98. De FabreguesO. DotJ. Abu-SubohM. Long‐term safety and effectiveness of levodopa‐carbidopa intestinal gel infusion.Brain Behav.201778e0075810.1002/brb3.758 28828219
     [Google Scholar]
  99. ZibettiM. RizzoneM. MerolaA. Sleep improvement with levodopa/carbidopa intestinal gel infusion in Parkinson disease.Acta Neurol. Scand.20131275e28e3210.1111/ane.12075 23311399
     [Google Scholar]
  100. De CockV.C. DodetP. Leu-SemenescuS. Safety and efficacy of subcutaneous night-time only apomorphine infusion to treat insomnia in patients with Parkinson’s disease (APOMORPHEE): A multicentre, randomised, controlled, double-blind crossover study.Lancet Neurol.202221542843710.1016/S1474‑4422(22)00085‑0 35429481
     [Google Scholar]
  101. SuzukiK. Current update on clinically relevant sleep issues in Parkinson’s disease: A narrative review.J. Parkinsons Dis.202111397199210.3233/JPD‑202425 33896849
     [Google Scholar]
/content/journals/cnsnddt/10.2174/0118715273314675240820191447
Loading
Sleep-Related Disorders in Parkinson's Disease: Mechanisms, Diagnosis, and Therapeutic Approaches
CNS & Neurological Disorders - Drug Targets (Formerly Current Drug Targets - CNS & Neurological Disorders) 24, 132 (2025); https://doi.org/10.2174/0118715273314675240820191447
/content/journals/cnsnddt/10.2174/0118715273314675240820191447
/content/journals/cnsnddt/10.2174/0118715273314675240820191447
Loading

Data & Media loading...


  • Article Type:     Review Article
Keyword(s): daytime sleepiness; obstructive sleep apnoea; Parkinson's disease; quality of life; REM sleep behaviour disorder; restless legs syndrome; sleep-related disorders

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test